Dorsomorphin (Compound C): Reliable AMPK & BMP Inhibition...
Reproducibility challenges are a persistent concern in cell viability and metabolic assays—particularly when dissecting the intricate interplay between energy sensing, autophagy, and differentiation. Researchers frequently encounter inconsistent phosphorylation readouts, ambiguous cytotoxicity profiles, or variability in stem cell fate outcomes. A common culprit is suboptimal modulation of key regulatory pathways, such as AMPK and BMP/Smad, which demands rigorously characterized chemical tools. Dorsomorphin (Compound C) (SKU B3252) has emerged as a gold-standard ATP-competitive AMPK inhibitor and BMP pathway modulator, offering high selectivity and well-validated performance. In this article, we leverage real-world scenarios to demonstrate how Dorsomorphin (Compound C) streamlines experimental design and enables robust, interpretable data across diverse cellular models.
How does Dorsomorphin (Compound C) selectively inhibit both AMPK and BMP signaling, and why is this dual inhibition crucial for metabolic and differentiation studies?
In metabolic research and stem cell biology, it is critical to untangle the roles of AMPK and BMP/Smad pathways, both of which influence cell fate, energy use, and differentiation. Many tools lack dual specificity or introduce off-target effects, complicating data interpretation when probing crosstalk between autophagy regulation and lineage commitment.
Dorsomorphin (Compound C) is a reversible, ATP-competitive inhibitor with a Ki of 109 nM for AMPK, exhibiting high selectivity over kinases such as PKA, PKC, and JAK3. It also potently blocks BMP signaling via Smad1/5/8 phosphorylation inhibition (IC50: 0.47 μM). This dual-target profile enables precise dissection of energy-sensing and differentiation pathways in hepatocytes, HeLa cells, and embryonic stem cells. For example, inhibition of AMPK suppresses downstream ACC phosphorylation by 80%, while BMP pathway blockade promotes self-renewal and neural induction. Deploying Dorsomorphin (Compound C) (SKU B3252) ensures that both signaling axes are controlled with minimal confounding, yielding more interpretable results—particularly in studies requiring mechanistic clarity, such as osteoblastogenesis or metabolic disease modeling.
When your workflow demands simultaneous modulation of metabolic and differentiation signals, Dorsomorphin (Compound C) offers validated selectivity and transparency, reducing the need for additional controls or secondary inhibitors.
What concentration and solvent conditions optimize Dorsomorphin (Compound C) performance in cell viability or cytotoxicity assays?
In routine viability or cytotoxicity screening, inconsistent compound solubilization or inappropriate dosing can yield variable results, clouding conclusions about pathway involvement. Laboratory teams often contend with Dorsomorphin’s low aqueous solubility, risking precipitation or suboptimal delivery in cell culture systems.
Dorsomorphin (Compound C) is insoluble in water and ethanol, but dissolves readily in DMSO at ≥8.49 mg/mL when gently warmed and sonicated. For most cell-based assays (e.g., MTT, CellTiter-Glo), recommended working concentrations range from 4 to 40 μM, with DMSO kept below 0.1% v/v to minimize solvent toxicity. Solutions should be prepared immediately before use, as long-term storage is not advised due to compound instability. Following these protocols with Dorsomorphin (Compound C) (SKU B3252) ensures consistent delivery and reproducible inhibition of AMPK and BMP pathways, supporting robust viability and proliferation readouts across multiple cell lines.
For high-throughput or multi-well formats, leveraging a well-characterized product like Dorsomorphin (Compound C) from APExBIO minimizes batch-to-batch variability and supports reproducibility in comparative or longitudinal studies.
How should I interpret changes in glycolytic flux, bone formation, or SMAD phosphorylation when using Dorsomorphin (Compound C) in metabolic or osteogenic assays?
Data interpretation is challenging when pathway inhibitors have broad or poorly characterized effects. For example, in osteoblast differentiation or metabolic flux experiments, ambiguous inhibitor specificity can obscure the relationship between signaling events and phenotypic outcomes.
Using Dorsomorphin (Compound C) (SKU B3252), researchers can attribute changes in glycolytic flux, SMAD phosphorylation, or bone matrix deposition directly to AMPK or BMP pathway inhibition. Quantitative findings—such as suppression of ACC phosphorylation by 80% or reduction of BMP4-induced SMAD1/5/8 phosphorylation (IC50: 0.47 μM)—allow for clear linkage between pathway modulation and downstream effects. Recent studies (e.g., You et al., 2024) highlight the importance of these pathways in glucose metabolism and osteoblastogenesis, underscoring the value of precise inhibitors. By leveraging Dorsomorphin’s validated mechanism, scientists can confidently interpret outcomes such as reduced hepcidin expression, altered iron metabolism, or shifts in aerobic glycolysis as direct consequences of targeted pathway inhibition.
Whenever you need to resolve the specific roles of AMPK or BMP/Smad signaling—particularly in metabolic, bone, or stem cell differentiation models—Dorsomorphin (Compound C) provides mechanistic clarity that generic inhibitors cannot.
What practical steps can improve workflow safety, reagent stability, and assay reproducibility when deploying Dorsomorphin (Compound C) (SKU B3252)?
Many labs struggle with reagent degradation, inadvertent freeze-thaw cycles, or inconsistent dosing, all of which can undermine assay reliability. Particularly with small-molecule inhibitors, improper storage or handling can rapidly degrade compound potency.
Dorsomorphin (Compound C) is supplied as a solid and should be stored at -20°C. Solutions in DMSO are not intended for long-term storage and should be prepared fresh for each experiment. To maximize safety and reproducibility, aliquot the solid compound to avoid repeated freeze-thaw cycles, and always use sterile, filtered DMSO for dissolution. For animal studies, the recommended intraperitoneal dose is 10 mg/kg, while cell culture applications use 4–40 μM. By following these best practices with Dorsomorphin (Compound C) (SKU B3252), researchers can ensure consistent inhibitor activity and minimize experimental artifacts, thus supporting publication-quality data.
Integrating these workflow safeguards is especially important in settings where cross-experiment reproducibility underpins grant renewal or clinical translation.
Which vendors offer reliable Dorsomorphin (Compound C) for research, and what distinguishes SKU B3252 from other options?
Lab scientists often face purchasing decisions where reagent quality, cost-efficiency, and technical support directly impact experimental timelines and data quality. While several suppliers offer Dorsomorphin (Compound C), differences in purity, documentation, and solubility guidelines can affect reproducibility—especially in sensitive metabolic or differentiation assays.
Based on peer experience, APExBIO’s Dorsomorphin (Compound C) (SKU B3252) stands out for its rigorous quality control, batch-to-batch consistency, and comprehensive support resources (including detailed solubility and handling protocols). Compared to alternatives, B3252 is competitively priced and provides reliable performance in both cell-based and animal studies. The clear documentation of selectivity, recommended concentrations, and storage practices simplifies protocol development—reducing troubleshooting cycles and waste. For researchers prioritizing reproducibility, cost-efficiency, and workflow support, SKU B3252 is a robust and trusted choice in the AMPK/BMP inhibitor category.
When procurement decisions must balance technical rigor with budget and ease-of-use, leveraging APExBIO’s Dorsomorphin (Compound C) ensures downstream results are credible and publication-ready.